List view / Grid view
In this issue, find articles discussing how high-throughput experimentation can enhance automated molecular discovery, why bNAbs present a promising COVID-19 treatment and how a novel rhinovirus vaccine was developed. Also included are features on immuno-oncology, cell line development and assays.
Simple Western™ is an automated capillary immunoassay that produces publication-ready data to meet the highest standards of data integrity and rigor.
Working with RNA requires rigorous nuclease contamination controls in place. Stock up on Nuclease-Free tubes tips and buffers #Back2Lab
Researchers have developed a technique utilising antibodies to tag disease-causing proteins, to treat the underlying causes of disease.
Researchers have shown antibodies induced by the Pfizer and Moderna vaccines are less effective at neutralising certain SARS-CoV-2 variants.
New podcast on SARS-CoV-2 molecular testing: From human sample analysis to Wastewater Surveillance.
RiboMinus Bacteria 2.0 Transcriptome Isolation Kits perform efficient transcriptome enrichment from total bacterial RNA. Improve your RNA extraction from bacteria today.
A new study has revealed that immunoglobulin-M antibodies recognise microvesicles, which are critical for the progression of thrombosis.
Six antibodies specific to the circumsporozoite protein of the malaria parasite have shown promise as therapeutic interventions, a study has shown.
A monoclonal antibody (mAb) cocktail, that targets sites on the Spike protein other than the E484K residue, can neutralise SARS-CoV-2.
A new nanoparticle-based vaccine has demonstrated success in ferret models of COVID-19, inducing strong neutralising antibodies against SARS-CoV-2.
26 February 2021 | By Domain Therapeutics
Watch our on-demand webinar which focused on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Sino Biological has developed 80+ mutant proteins covering the newest mutations identified in SARS-CoV-2 variants, such as UK's B.1.1.7, Brazil's P.1.
